<DOC>
	<DOCNO>NCT02333071</DOCNO>
	<brief_summary>A Phase 3 , Randomized , Double-blind , Placebo-controlled , Parallel-group Trial Open-label Extension evaluate efficacy bremelanotide ( BMT ) , administer subcutaneously ( SC ) need basis treatment HSDD ( without decrease arousal ) premenopausal female .</brief_summary>
	<brief_title>A Phase 3 , Randomized , Double-blind , Placebo-controlled , Parallel-group Trial With Open-label Extension</brief_title>
	<detailed_description>This multicenter , randomize , placebo-controlled , parallel group study 80 site United States America ( USA ) Canada evaluate efficacy safety fix dose SC BMT versus placebo as-needed basis condition home use premenopausal woman HSDD ( without decrease arousal ) . The study consist 2 phase : ( 1 ) 32-week phase include randomize , double-blind treatment period precede screening/baseline period ( Core Study ) ( 2 ) 52 week open-label treatment phase ( Extension Phase ) . Primary Objective â€¢ To evaluate efficacy bremelanotide ( BMT ) , administer subcutaneously ( SC ) need basis treatment HSDD ( without decrease arousal ) premenopausal female . Secondary Objectives - To evaluate efficacy BMT premenopausal woman double-blind Core Study , assess subject response questionnaires measure sexual function , treatment satisfaction , distress associate sexual dysfunction . - To evaluate safety BMT premenopausal woman double-blind Core Study . - To evaluate safety long-term therapy BMT open label Extension Phase . - To evaluate efficacy long-term therapy BMT open-label Extension Phase .</detailed_description>
	<mesh_term>Hypokinesia</mesh_term>
	<mesh_term>Sexual Dysfunctions , Psychological</mesh_term>
	<mesh_term>alpha-MSH</mesh_term>
	<criteria>Main Has meet diagnostic criterion HSDD least 6 month Is willing able understand comply study requirement Has normal pelvic examination screen Main Subjects generally healthy premenopausal female psychological , gynecological urological condition might contribute sexual dysfunction , compromise study participation , confound interpretation study result Not currently treatment sexual dysfunction willing forego treatment course clinical trial</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>HSDD</keyword>
	<keyword>Female Sexual Desire Disorder</keyword>
</DOC>